Background The influenza A (H1N1pdm09) [pH1N1] virus resulted in intensive care unit (ICU) admissions, acute respiratory distress syndrome (ARDS), and death.
Approximately 23-34% of patients hospitalized in the United States were admitted to an intensive care unit (ICU). [3] [4] [5] [6] [7] Globally, ICU admissions were associated with chronic comorbidities, 5, [8] [9] [10] pregnancy, 11 obesity, 6,10 pneumonia, 5, 7, 10 and delay in influenza antiviral treatment. 5, 7, 10, 11 Acute respiratory distress syndrome (ARDS) was a common complication and a significant cause of mortality among ICU patients with pH1N1 virus infection. 5, 7 Critically ill patients with pH1N1 infection have been previously described, [12] [13] [14] [15] [16] [17] [18] but a few studies have focused on ICU patients hospitalized in the United States. We describe the clinical characteristics, including severe outcomes of ARDS and death and their association with different factors such as early antiviral treatment, among children and adults hospitalized in an ICU with pH1N1 virus infection in the United States during the spring and fall pandemic waves.
Methods
The source of patient data included in this analysis was two previously described national pH1N1 virus hospitalization case-series conducted in the United States during spring and fall 2009. 5, 7 Patients included in these case-series had laboratory-confirmed pH1N1 virus by real-time reverse-transcriptase polymerase chain reaction; testing was clinically driven.
In the spring (May 1-June 9, 2009), the first hospitalized pH1N1 patients reported to CDC were sequentially sampled; participation from 24 states where disease occurred yielded 25% of the total cases reported during the surveillance period. 5 In the fall (September 1-October 31, 2009), patients were sampled based on probability of selection proportional to the number of hospitalized cases reported to CDC; participation from 40 states yielded <2% of the total cases reported during the surveillance period. 7 Both spring and fall case-series were part of the emergency public health practice response to assess illness severity during the pH1N1 virus pandemic and were deemed not to be research in accordance with the federal human subjects protection regulations at 45 Code of Federal Regulations 46AE101c and 46AE102d and CDC's Guidelines for Defining Public Health Research and Public Health Non-Research; participation by the state and local health departments was voluntary.
For this analysis, we included patients with pH1N1 infection admitted to an ICU from the overall hospitalization case-series; this represented 34 states in the United States. Using a standard form, demographic and clinical information, including receipt of mechanical ventilation, ARDS as diagnosed by treating physicians, and death status were abstracted from medical charts by infection control practitioners, physicians, nurses, and epidemiologists at state and local health departments and reported to CDC. We collected information on all symptoms including date of onset for each symptom; the first day for any symptom was considered illness onset day 0. Day of hospital admission was considered hospital day 0; for transfer patients, date of admission related to the first hospitalization was used. Body mass index (BMI) was calculated as the weight in kilograms divided by the square of height in meters for non-pregnant ICU patients ‡2 years of age to determine normal range (BMI < 30AE0), obesity (BMI 30AE0-39AE9 in adults or BMI percentile 95-100 in children), or morbid obesity (BMI ‡40 in adults only). Pneumonia status was based on admission chest radiograph reports. ARDS status was determined by review of the admission history, problem list, and discharge summary. If any of these areas of the medical chart listed ARDS, the patient was considered to have ARDS.
We conducted bivariate analyses to investigate associations with ARDS and death, using the chi-square or Fisher's exact test to compare categorical variables and the Wilcoxon rank-sum test to compare continuous variables (P £ 0AE05). All analyses were performed in sas version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results

Clinical characteristics
Of 527 pH1N1 hospitalized patients, 154 (30%) were admitted to an ICU, including 68 ⁄ 272 (26%) spring and 86 ⁄ 255 (34%) fall hospitalizations. The majority of patients (77%) were <50 years of age, and race ⁄ ethnicity was principally non-Hispanic white (40%), Hispanic (22%), or black (22%) ( Table 1) .
Forty percent of patients were admitted to the hospital £2 days after illness onset, including 55% of children and 34% of adults. Sixty-four percent of patients were admitted to an ICU on the same day as hospital admission. On hospital admission, most ICU patients had a history of fever (97%), cough (89%), or shortness of breath (77%) and had documented tachypnea (54%) and tachycardia (80%) ( Table 2 ). The median length of hospital stay was 8 days, and median ICU length of stay was 4 days.
The majority of patients (65%) had at least one underlying medical condition ( Table 2 ). In children, neurological disease (30%), including neurocognitive dysfunction, neuromuscular disease, and seizure disorder, was most common. Asthma (23%) was most common among adult patients. Eleven (7%) patients were pregnant, eight (73%) of whom were in the third trimester. Of the 98 (73%) non-pregnant persons aged ‡2 years for whom height and weight were available, six (30%) children and 23 (29%) adults were obese, and an additional 21 (27%) adults were morbidly obese.
Diagnostic findings
Equal proportions of patients (22%) with available admission white blood counts (n = 146) had leukopenia (white cell count < 5000 per mm 3 ) and leukocytosis (white cell count > 11 000 per mm 3 ). The majority of patients (71%) had radiographic findings consistent with pneumonia ( Table 2) . Bacterial infection was confirmed by admission blood culture, sterile respiratory site culture, or urine antigen test in 11 patients, seven of whom died, including three patients with ARDS. Organisms identified were methicillinresistant Staphyloccus aureus (2), methicillin-sensitive S. aureus (2), S. aureus of unknown sensitivity (1), Streptococcus pneumoniae (3), group A streptococcus (GAS) (1), S. pneumoniae and GAS co-infection (1), and Escherichia coli (1).
Treatment
The majority of patients received influenza antiviral agents (83%); oseltamivir (98%) was most commonly used. The median time from illness onset to antiviral treatment was 4 days among 125 ICU patients with available antiviral agent initiation dates; 29% of patients received antiviral agents £2 days after illness onset, including 38% of children and 25% of adults (Table 2 ). In addition, 36% of patients received antiviral agents between 3 and 5 days after illness onset and 35% of patients were treated ‡6 days after illness onset. Receipt of antiviral agents in relation to day of admission was the following: 5% before admission, 48% on admission, 23% £2 days after admission, and 24% >2 days after admission.
Outcomes
The proportion of hospitalized patients admitted to an ICU in the spring was lower than in the fall (25% versus 34%, P = 0AE03). However, other indicators of severe illness were similar between the two waves including the proportion of ICU patients requiring mechanical ventilation (63% versus 53%, P = 0AE2), with ARDS (43% versus 33%, P = 0AE3), and who died (28% versus 21%, P = 0AE3).
Eighty-nine (58%) (23 children and 66 adults) patients were mechanically ventilated ( Table 2 ). Patients requiring mechanical ventilation compared with patients not requiring mechanical ventilation were less likely to have asthma (18% versus 32%, P = 0AE04) and more likely to have pneumonia (82% versus 54%, P < 0AE01) and die (37% versus 6%, P < 0AE01).
ARDS developed in 48 of 128 (38%) patients (10 children and 38 adults, Table 2 ). Patients with ARDS compared with patients without ARDS had a longer median time from illness onset to hospital admission (5 versus 3 days) and were more likely to be morbidly obese (36% versus 19%), have pneumonia (91% versus 56%), and die (48% versus 8%) but less likely to have a neurological disease (6% versus 20%) ( Table 3) . Patients with ARDS were not more likely to have asthma (19% versus 33%, P = 0AE09) than patients without ARDS. Patients with ARDS and those without ARDS were equally likely to receive influenza antiviral agents, but patients with ARDS were less likely to receive treatment £2 days after admission (64% versus 84%, P = 0AE03). Compared with patients who received treatment ‡6 days after illness onset, patients treated £2 days and between 3 and 5 days after illness onset were less likely to develop ARDS ( Figure 1 , Table 3 ).
Among 37 (24%) ICU patients who died, nine were children and 28 were adults ( Table 2) . Patients who died compared with those who survived had a longer median time from illness onset to hospital admission (5 versus 3 days) and were more likely to have pneumonia (91% versus 64%) and ARDS (79% versus 25%) but less likely to have asthma (11% versus 28%) ( Table 3) . Patients who died and those who survived were equally likely to receive influenza antiviral agents, including within 2 days of admission (61% versus 78%; P = 0AE08). Compared with patients who received treatment ‡6 days after illness onset, patients treated £2 days after illness onset were less likely to die ( Figure 1 , Table 3 ).
Discussion
We describe a large national case-series including both children and adults hospitalized in an ICU with pH1N1 virus infection in the United States. Among 154 pH1N1 patients hospitalized in an ICU during the spring and fall pandemic waves, almost two-thirds required mechanical ventilation, nearly 40% developed ARDS, and one-quarter died. The majority of ICU patients in this analysis were <50 years old or had underlying medical conditions. While asthma was the most common underlying medical condition, patients with asthma were not more likely to develop ARDS or die. Early treatment with influenza antiviral agents was associated with survival and non-progression to ARDS, especially when initiated £2 days after illness onset.
Critical illness has been previously described around the world; a review of key studies is highlighted in Table 4 . [12] [13] [14] [15] [16] [17] [18] While case definitions and case ascertainment methods varied, several findings were similar across studies. Globally, critically ill pH1N1 patients were younger adults [12] [13] [14] [15] [16] with chronic lung disease [13] [14] [15] [16] or obesity [12] [13] [14] [15] [16] and young children with chronic lung disease or neurological disorders. 17, 18 The need for mechanical ventilation ranged from 65% to 93%, 12, 13, [15] [16] [17] [18] ARDS ranged from 49% to 64%, 14, 15 and mortality ranged from 7% to 41%. [12] [13] [14] [15] [16] [17] [18] Few studies were able to assess the impact of treatment with influenza antiviral agents on critical illness; however, when data have been available, antiviral treatment 12 has been associated with survival. While the critical illness literature covers a broad spectrum of populations, only a few United States ICU case-series have been described to date. In this analysis, similar to other ICU case-series, neurological disorders and asthma were the most common underlying medical conditions in children and adults, respectively (Table 4) , and are known to be high-risk conditions for influenza-associated complications. 19 Persons with neurological disorders infected with influenza virus are at risk for respiratory failure 20 and death 18, 21 because of compromised respiratory function, inability to handle respiratory secretions, or malnutrition. [22] [23] [24] However, in this analysis, patients with neurological disorders were not more likely to develop ARDS or die; this may be due to the small number of patients with neurological disorders in our study. Interestingly, in this analysis, patients with asthma were not at greater risk for ARDS and were less likely to die. The severity and course of illness among persons with asthma with influenza infection depends on multiple factors including the immunologic response to viral infections, airway hyper-responsiveness caused by atopy, allergens, and other environmental factors, as well as baseline control of asthma. 25 Patients included in our analysis (26) 37 (24) *Interquartile range. **Patients who are pregnant, immunocompromised (either because of medications or immune disorders including human immunodeficiency syndrome), or have chronic pulmonary (including asthma or chronic obstructive pulmonary disease), cardiovascular (excludes hypertension), renal, hepatic, hematological, neurological, or metabolic disease (including diabetes) are considered at high-risk for influenza-related complications. ***Obesity and morbid obesity are mutually exclusive.
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e137 may have been admitted to an ICU more readily if they had a history of asthma as a precaution and not because of the severity of their present illness; this would bias our analysis to demonstrating less severe outcomes in this group. In addition, morbid obesity, which emerged as a risk factor for severe influenza infection during the 2009 pandemic, 26 was more common among ARDS patients in our analysis. Adipose tissue has been hypothesized to reduce macrophage activity and cytokine production and contribute to pro-inflammatory state predisposing obese individuals to infection. 27 Further, adipose tissue that has accumulated around the rib cage and abdomen may decrease lung compliance and increase the risk of airway closure and ventilation-perfusion mismatch. 28 While influenza vaccination is now recommended for all persons ‡6 months old, 29 in light of vaccine supply and demand and future pandemic preparedness, a better understanding of the relationship between influenza and underlying conditions that can lead to severe outcomes is necessary. ARDS affected nearly 40% of patients in our ICU caseseries. While the proportion of ARDS was not as high as in other studies of critically ill pH1N1 patients in which 49-64% of patients had ARDS, 14, 15 this may have been due to variable study periods, study populations, ARDS definitions, and differences in assessment of ARDS (Table 4) . The proportion of pH1N1 ICU patients with ARDS in this analysis was substantially higher than reported in another ICU case-series that focused on seasonal influenza virus infection (23%). 30 Results from both animal studies and human autopsy reports indicate that pH1N1 virus infection caused severe diffuse alveolar damage that likely led to more severe lower-tract respiratory disease and respiratory failure than has been seen with seasonal influenza infections in the past. [31] [32] [33] [34] While our data is observational, it suggests that early treatment with influenza antiviral agents, especially when initiated £2 days after illness onset, may be beneficial in preventing ARDS or death. Patients who received antiviral treatment between 3 and 5 days after illness onset were less likely to develop ARDS but equally likely to die compared with patients treated ‡6 days after illness onset. The reasons for this discrepancy are unclear but could be related to persons dying of causes other than ARDS, misclassification of ARDS status, or because of the low number of deaths in this analysis. While the greatest benefit associated with antiviral treatment has been noted for patients who receive early antiviral therapy, some studies have shown that treatment with antiviral agents >2 days from illness onset may avert influenza-associated complications. 35 Our results underscore the importance of early influenza antiviral treatment among hospitalized 5, 7, 9, 36 and critically ill 37 patients with influenza and the need for clarity on the optimal timing in which antivirals still have benefit. Our data are subject to limitations. The patients described were derived from two hospitalization case-series that used different sampling methods. 5, 7 However, data from both periods were nationally representative of hospitalizations from areas in the United States where peak disease activity was occurring at the time. Patients included in this analysis were laboratory-confirmed for pH1N1 virus and may not be representative of all ICU patients with pH1N1 infection who were not tested. Deaths occurring after hospital discharge, which could have been related to the influenza admission, were not captured. Despite the use of a standard data collection form, not all information was collected for all patients, including influenza vaccination status (pH1N1 vaccine was not readily available during the study); this limits our ability to assess these interventions; however, the study was not designed to address these specific questions. While we attempted to collect detailed clinical information on each patient, variables that could be included in severity scores were not available for most patients. ARDS status was also not always available. In addition, variables, including ARDS and history of asthma, were based on chart review and not a standardized clinical assessment, potentially resulting in misclassification. To reduce further misclassification of ARDS, missing ARDS data were not imputed. Because not all data elements were collected for all patients, we did not have an adequate sample size to conduct a multivariable analysis.
The pH1N1 virus caused significant morbidity in the United States, 2 leading to a substantial number of ICU admissions and deaths. [3] [4] [5] [6] [7] Influenza vaccination is the primary tool for preventing infection and is recommended for all persons aged ‡6 months. 29 However, because of varying and suboptimal influenza vaccination rates, and as influenza vaccine effectiveness is not 100%, early influenza antiviral treatment is a key element needed to reduce morbidity and mortality from influenza. All persons with suspected or confirmed influenza virus infection requiring hospitalization or patients with progressive, severe, or complicated illness, including those admitted to an ICU, should be given influenza antiviral agents as early as possible, regardless of their prior vaccination status. ARDS, acute respiratory distress syndrome; pH1N1, pandemic influenza A (H1N1pdm09).
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